Immutep Limited American Depositary Shares (NASDAQ: IMMP)
The complaint alleges Defendants provided investors with material information concerning Immutep’s TACTI-004 Phase III trial evaluating eftilagimod alfa (efti) in patients with advanced lung cancer. Defendants’ statements included, among other things, Immutep’s positive assertions of TACTI004’s future trial success based on continuing positive efficacy and safety readouts, particularly following positive top-line results from Immutep’s prior TACTI-002 and INSIGHT-003 studies.